Ameritas Investment Partners Inc. Decreases Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ameritas Investment Partners Inc. lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 23,526 shares of the medical equipment provider’s stock after selling 39 shares during the period. Intuitive Surgical comprises 0.6% of Ameritas Investment Partners Inc.’s holdings, making the stock its 28th largest position. Ameritas Investment Partners Inc.’s holdings in Intuitive Surgical were worth $10,465,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ISRG. Advisors Asset Management Inc. increased its stake in Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after purchasing an additional 1,129 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after buying an additional 9,869 shares during the last quarter. HCR Wealth Advisors lifted its holdings in shares of Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after buying an additional 217 shares during the period. Artisan Partners Limited Partnership increased its position in Intuitive Surgical by 53.5% during the fourth quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock valued at $21,541,000 after acquiring an additional 22,264 shares during the last quarter. Finally, SWP Financial LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $255,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of several recent research reports. Robert W. Baird increased their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Truist Financial boosted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Evercore ISI decreased their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research report on Friday, July 19th. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Insider Buying and Selling

In other news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $486.20 on Friday. The business’s 50 day moving average price is $468.01 and its 200-day moving average price is $424.86. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.18. The firm has a market capitalization of $172.46 billion, a PE ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the company posted $1.18 EPS. The business’s revenue was up 14.5% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.